摘要
目的探讨阿托伐他汀对急性脑梗死患者血浆NO及血小板α颗粒膜蛋白(GMP-140)水平的影响。方法94例急性脑梗死患者随机分为治疗组(阿托伐他汀组)(48例)和对照组(46例),采用硝酸酶还原法和双抗体夹心酶联免疫吸附法分别测定治疗组和对照组治疗前及治疗4周后血浆NO及GMP-140含量,并同时按照欧洲卒中评分(ESS)标准进行评分。结果治疗后治疗组和对照组血浆NO及GMP-140水平均较治疗前明显下降(P<0·01),且治疗组较对照组下降明显(P<0·05);治疗组和对照组ESS分值明显高于治疗前(P<0·01),但治疗组和对照组的ESS分值无明显差异(P>0·05)。结论阿托伐他汀能降低急性脑梗死患者血浆NO及GMP-140的水平,从而减轻缺血性脑损伤,起到保护脑组织的作用。
Objective To investigate the effect of atorvastain on plasma levels of nitric oxide（NO） and alpha-granule membrance protein-140（GMP-140） in patients with acute cerebral infarction. Methods＇ 94 cases with acute cerebral infarction were randomly divided into the atorvastain group（48 cases） and the control group（46 cases）. Plasma NO and GMP-140 were determined by the method of nitrate reductase and enzyme-linked immunosorbent assay in atorvastain group and control group at moment of hospitalization and after four weeks. Results Plasma NO and GMP-140 of atorvastain group after treatment were statistically lower than that of controls（ P〈0.01 ）. And the level of atorvastain group were statistically lower than that of controls（ P 〈0.05）. European stroke scale（ESS） of atorvastain group and controls after treatment were higher than them before treatment（ P〈 0.01 ）, but ESS has no significant difference between atorvastain group and controls after treatment（ P 〉 0.05）. Conclusion Atorvastain can reduce plasma levels of NO and GMP-140 in patients with acute cerebral infarction. It can ameliorate brain injury after ischemia and has protective effect on the ischemia cerebral tissue.
出处
《中国基层医药》
CAS
2006年第7期1071-1072,共2页
Chinese Journal of Primary Medicine and Pharmacy
关键词
脑梗死
阿托伐他汀
一氧化氮
Α颗粒膜蛋白
Brian infarction
Atorvastain
Nitric oxide
Alpha-granule membrane protein
